NLRP3 and adult-onset Still disease: IL-1 inhibitors, including canakinumab, rilonacept, and anakinra, have been approved for the treatment of rheumatoid arthritis,535 auto-inflammatory diseases,536 cryopyrin-associated periodic syndromes (CAPS),537,538 adult-onset Still’s disease (AOSD).539 Their applications in cancer therapy have also been under investigation.